Medical device manufacturer Philips will halt all sales of its sleep apnea machines amid fears about the devices’ links to cancer.

In 2021, the company’s CPAP machines, used to treat the sleeping disorder, were found to be blowing gas and foam into users’ airways as they slept, putting them at increased risk of tumors. 

The discovery led to the company recalling more than 5million machines, but attempts to repair and replace affected machines has been dragging on for years. 

Now, the FDA and Justice Department have forced Philips to halt all new sales until they address the problem with the old devices.

CPAP masks come in various styles and sizes to accommodate different preferences and facial structures. They consist of a motor that draws in room air and pressurizes it. The pressurized air is delivered through a hose to a mask worn over the nose, mouth, or both

An estimated 30 million Americans have sleep apnea, a condition characterized by pauses in breathing or choking for air during sleep.

But only about 6 million have gotten a diagnosis, while about 5 million Americans have at least tried using a CPAP device.

Sleep apnea is often associated with snoring and sudden gasps for air, but continuous positive airway pressure, or CPAP, machines are an effective means to combat the condition that causes sufferers to briefly stop breathing multiple times per night.

The machine delivers a steady stream of mild air pressure through a tube connected to a snorkel-like mask to keep the airways from collapsing.

In addition to the costly recall, Philips is facing over 700 lawsuits claiming the devices contributed to patients’ cancers and other health problems.

Philips Chief Executive Officer Roy Jakobs said: ‘Patient safety and quality remain Philips’ highest priority across the company.

‘Resolving the consequences of the Respironics recall for our patients and customers is a key focus area and I acknowledge and apologize for the distress and concern caused. 

‘We are fully committed to complying with the consent decree, which is an important step and provides a clear path forward.’

It’s a major setback for the company which is a leader in the sleep device market, which is estimated to grow from a value of $5 billion in 2021 to $7.2 billion in 2030.

The FDA, for its part, said: ‘Until there is a finalized agreement that has been signed and filed with the court, we cannot comment further.’ 

A 2021 recall saw Philips pull millions of their Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP), and mechanical ventilator devices for the same reason – foam used to dampen the sound of the machine can degrade and enter the airway, which carries a risk of cancer.

The foam particles can potentially induce irritation and inflammation in the respiratory system, which is especially threatening for individuals with pre-existing lung conditions or poor heart-lung function.

Exposure to deteriorated foam can also cause inflammatory responses, headaches, asthma, and adverse effects on other organs, such as the kidneys and liver, including ‘toxic carcinogenic effects.’

The foam in the recalled CPAP machines was made with polyester-based polyurethane which was found to degrade into smaller particles and toxic gases that would be inhaled by the user. 

In addition to potentially causing asthma, respiratory infections, and organ damage, this foam is also linked to lung, bladder, kidney, breast, stomach, liver, thyroid, and blood cancers sych as leukemia and Non-Hodgkin lymphoma.  

Philips Respironics has documented numerous complaints related to the discovery of black debris or particles in the part of the machine that feeds air into the sleeping person. 

There have also been reports of various symptoms like headaches, upper airway irritation, cough, chest pressure, and sinus infections.

Philips is currently facing more than 700 suits over claims that its products caused users to develop cancers and other health problems. One of those suits comes from Kansas-native Robert Dix who filed suit against Philips in April 2022. 

Mr Dix was prescribed and purchased a Philips CPAP machine in March 2016 but later suffered injuries ‘including harm to his respiratory system, cellular damage, DNA damage, and lung cancer.’  

Philips said it has been conducting testing on its CPAP machines since the 2021 recall and that using the devices ‘is not expected to result in appreciable harm to health in patients.’

Last fall, Philips reached a $479 million partial settlement in a class action suit over design flaws that caused carcinogenic foam specks to make their way into the user’s airways.

Sleep apnea becomes more common with advancing age, and more men experience it than women. 

It occurs in about 3 percent of normal-weight individuals but affects more than 20 percent of obese people.

Sufferers snore, choke, and gasp 20 to 30 times every hour throughout the night and, as a result, unknowingly and repeatedly wake up, which means the body does not get enough rest.

To test for sleep apnea, sleep experts will connect a person to equipment that monitors breathing patterns and blood oxygen levels while they sleep, commonly known as a sleep study.

When breathing stops for 10 seconds or more at a time, oxygen levels in the blood fall, increasing the risk of hypertension, stroke, and heart attacks later in life.


Philips Respironics – Certain Ventilator Devices

Manufactured before April 26, 2021

Trilogy 100, Trilogy 200 and BiPAP A30/A40 Series Device Models

Product codes: 1076581, 1076582, 1076583, 1111145, 1111171, AU1054096 

Philips Respironics – Certain CPAP and Bi-Level PAP Devices

Manufactured before April 26, 2021

E30 (Emergency Use Authorization), DreamStation ASV, DreamStation ST AVAPS, SystemOne ASV4, C-Series ASV, C-Series S/T and AVAPS, OmniLab Advanced+, SystemOne (Q-Series), DreamStation, DreamStation Go 

Product codes: 133792, 209934, 235674, 257012, 257013, 295664, 285420, 327227, 335508

It is important that you register your device as soon as possible at the support website

Philips will write to affected consumers. Users and carers should review the information provided in the customer letter about the ongoing use of impacted devices. 

For further information, please contact the Philips Support Hotline on 1800 009 579.

Source: Product Safety 

Related Post